| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 43 | 2025 | 1132 | 10.020 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 43 | 2024 | 408 | 7.430 |
Why?
|
| Carcinoma, Hepatocellular | 26 | 2026 | 1003 | 5.130 |
Why?
|
| End Stage Liver Disease | 23 | 2025 | 191 | 4.710 |
Why?
|
| Liver Neoplasms | 27 | 2026 | 1394 | 4.630 |
Why?
|
| Hepatitis C, Chronic | 19 | 2023 | 366 | 4.400 |
Why?
|
| Hepatitis C | 16 | 2026 | 388 | 4.120 |
Why?
|
| Liver Diseases, Alcoholic | 10 | 2023 | 61 | 3.290 |
Why?
|
| Liver Cirrhosis | 36 | 2026 | 908 | 3.240 |
Why?
|
| Tissue and Organ Procurement | 8 | 2025 | 253 | 2.670 |
Why?
|
| Antiviral Agents | 18 | 2023 | 809 | 2.530 |
Why?
|
| Hepacivirus | 13 | 2023 | 273 | 2.400 |
Why?
|
| Waiting Lists | 14 | 2025 | 242 | 2.260 |
Why?
|
| Fatty Liver | 11 | 2026 | 222 | 2.140 |
Why?
|
| Coronavirus Infections | 5 | 2020 | 364 | 1.920 |
Why?
|
| Pneumonia, Viral | 5 | 2020 | 375 | 1.910 |
Why?
|
| Tissue Donors | 10 | 2025 | 501 | 1.850 |
Why?
|
| Nutrition Surveys | 23 | 2025 | 327 | 1.740 |
Why?
|
| United States | 64 | 2026 | 11820 | 1.610 |
Why?
|
| Hepatitis, Alcoholic | 6 | 2025 | 29 | 1.580 |
Why?
|
| Gastrointestinal Diseases | 3 | 2021 | 339 | 1.520 |
Why?
|
| Betacoronavirus | 5 | 2020 | 285 | 1.400 |
Why?
|
| Humans | 150 | 2026 | 130574 | 1.300 |
Why?
|
| Retrospective Studies | 48 | 2025 | 17653 | 1.190 |
Why?
|
| Pandemics | 15 | 2024 | 1154 | 1.140 |
Why?
|
| Risk Factors | 38 | 2025 | 10993 | 1.120 |
Why?
|
| Hospitalization | 13 | 2024 | 1932 | 1.110 |
Why?
|
| Graft Survival | 9 | 2025 | 462 | 1.050 |
Why?
|
| Middle Aged | 59 | 2026 | 28448 | 1.050 |
Why?
|
| Organ Transplantation | 2 | 2020 | 173 | 1.030 |
Why?
|
| Adult | 59 | 2026 | 31202 | 1.020 |
Why?
|
| Bile Duct Neoplasms | 2 | 2025 | 129 | 1.010 |
Why?
|
| Hepatitis B, Chronic | 5 | 2023 | 89 | 1.000 |
Why?
|
| Prevalence | 23 | 2026 | 2683 | 0.970 |
Why?
|
| Klatskin Tumor | 1 | 2025 | 10 | 0.940 |
Why?
|
| Alcohol Drinking | 3 | 2023 | 346 | 0.870 |
Why?
|
| Aged | 37 | 2026 | 20925 | 0.860 |
Why?
|
| Liver | 11 | 2025 | 1802 | 0.850 |
Why?
|
| Elasticity Imaging Techniques | 6 | 2024 | 152 | 0.850 |
Why?
|
| Male | 70 | 2026 | 64557 | 0.840 |
Why?
|
| Mortality | 4 | 2021 | 260 | 0.820 |
Why?
|
| Transplant Recipients | 3 | 2021 | 229 | 0.810 |
Why?
|
| Female | 69 | 2026 | 70509 | 0.780 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2023 | 51 | 0.780 |
Why?
|
| Length of Stay | 8 | 2025 | 1396 | 0.750 |
Why?
|
| Liver Failure | 3 | 2017 | 99 | 0.750 |
Why?
|
| Cause of Death | 15 | 2025 | 509 | 0.740 |
Why?
|
| Proton Pump Inhibitors | 3 | 2020 | 277 | 0.740 |
Why?
|
| Healthcare Disparities | 3 | 2022 | 506 | 0.710 |
Why?
|
| Coinfection | 2 | 2023 | 188 | 0.700 |
Why?
|
| Drug Overdose | 2 | 2020 | 70 | 0.700 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2025 | 230 | 0.690 |
Why?
|
| Liver Cirrhosis, Biliary | 2 | 2020 | 90 | 0.680 |
Why?
|
| Severity of Illness Index | 13 | 2025 | 3053 | 0.660 |
Why?
|
| Hepatic Encephalopathy | 5 | 2025 | 82 | 0.630 |
Why?
|
| Alcohol-Related Disorders | 1 | 2019 | 35 | 0.610 |
Why?
|
| Gastrointestinal Tract | 1 | 2021 | 224 | 0.600 |
Why?
|
| Gastrectomy | 2 | 2017 | 107 | 0.590 |
Why?
|
| Liver Diseases | 5 | 2023 | 382 | 0.590 |
Why?
|
| Probiotics | 1 | 2021 | 225 | 0.580 |
Why?
|
| Hepatitis C Antibodies | 1 | 2018 | 26 | 0.570 |
Why?
|
| DNA, Viral | 2 | 2018 | 451 | 0.540 |
Why?
|
| Diabetes Mellitus | 6 | 2024 | 895 | 0.530 |
Why?
|
| Mesenteric Veins | 1 | 2017 | 14 | 0.520 |
Why?
|
| Shock, Hemorrhagic | 1 | 2017 | 51 | 0.510 |
Why?
|
| Portal Vein | 1 | 2017 | 88 | 0.500 |
Why?
|
| Time Factors | 13 | 2024 | 6223 | 0.500 |
Why?
|
| Hospital Mortality | 4 | 2020 | 1072 | 0.500 |
Why?
|
| Skilled Nursing Facilities | 1 | 2016 | 7 | 0.490 |
Why?
|
| Transplants | 1 | 2016 | 38 | 0.490 |
Why?
|
| Treatment Outcome | 19 | 2025 | 12891 | 0.480 |
Why?
|
| Secondary Prevention | 1 | 2017 | 219 | 0.480 |
Why?
|
| Postoperative Complications | 3 | 2025 | 3114 | 0.470 |
Why?
|
| Proportional Hazards Models | 9 | 2025 | 1410 | 0.470 |
Why?
|
| Venous Thrombosis | 1 | 2017 | 169 | 0.460 |
Why?
|
| Cardiovascular Diseases | 7 | 2025 | 2099 | 0.450 |
Why?
|
| Health Care Costs | 4 | 2024 | 400 | 0.450 |
Why?
|
| HIV Infections | 3 | 2025 | 2012 | 0.440 |
Why?
|
| Hospital Costs | 1 | 2016 | 180 | 0.440 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2019 | 295 | 0.440 |
Why?
|
| Registries | 5 | 2025 | 1594 | 0.430 |
Why?
|
| Databases, Factual | 8 | 2022 | 1221 | 0.420 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2021 | 837 | 0.400 |
Why?
|
| Colonic Neoplasms | 1 | 2016 | 263 | 0.400 |
Why?
|
| Acute-On-Chronic Liver Failure | 2 | 2025 | 73 | 0.390 |
Why?
|
| Hepatitis, Viral, Human | 2 | 2023 | 43 | 0.380 |
Why?
|
| Risk Assessment | 13 | 2024 | 3712 | 0.380 |
Why?
|
| HIV | 2 | 2025 | 177 | 0.380 |
Why?
|
| Cholangiocarcinoma | 3 | 2024 | 125 | 0.380 |
Why?
|
| Cholangitis, Sclerosing | 2 | 2025 | 75 | 0.380 |
Why?
|
| Biliary Tract Neoplasms | 2 | 2024 | 21 | 0.380 |
Why?
|
| Young Adult | 13 | 2025 | 9991 | 0.360 |
Why?
|
| Patient Readmission | 3 | 2020 | 426 | 0.360 |
Why?
|
| Cohort Studies | 8 | 2025 | 5085 | 0.350 |
Why?
|
| Incidence | 8 | 2026 | 3344 | 0.350 |
Why?
|
| Laparoscopy | 1 | 2017 | 552 | 0.350 |
Why?
|
| Cross-Sectional Studies | 11 | 2025 | 3816 | 0.350 |
Why?
|
| Ascites | 4 | 2025 | 98 | 0.350 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2019 | 1076 | 0.340 |
Why?
|
| Aged, 80 and over | 10 | 2024 | 6773 | 0.340 |
Why?
|
| Health Policy | 2 | 2025 | 222 | 0.330 |
Why?
|
| Hypothyroidism | 2 | 2020 | 77 | 0.290 |
Why?
|
| Disease Progression | 7 | 2025 | 2201 | 0.280 |
Why?
|
| Inpatients | 4 | 2020 | 546 | 0.270 |
Why?
|
| Health Status Disparities | 3 | 2020 | 276 | 0.270 |
Why?
|
| Opioid-Related Disorders | 2 | 2021 | 295 | 0.260 |
Why?
|
| Esophageal and Gastric Varices | 2 | 2025 | 73 | 0.260 |
Why?
|
| Recurrence | 3 | 2021 | 1479 | 0.260 |
Why?
|
| Kidney Transplantation | 2 | 2025 | 564 | 0.250 |
Why?
|
| Cost of Illness | 3 | 2026 | 291 | 0.230 |
Why?
|
| Metabolic Diseases | 2 | 2024 | 140 | 0.220 |
Why?
|
| Preoperative Period | 3 | 2020 | 91 | 0.220 |
Why?
|
| Cholangitis | 1 | 2025 | 39 | 0.220 |
Why?
|
| Troponin | 1 | 2025 | 69 | 0.220 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2025 | 748 | 0.220 |
Why?
|
| Intention to Treat Analysis | 1 | 2024 | 60 | 0.220 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2026 | 142 | 0.210 |
Why?
|
| Donor Selection | 1 | 2024 | 58 | 0.210 |
Why?
|
| Depression | 3 | 2023 | 1318 | 0.210 |
Why?
|
| Pulse Wave Analysis | 1 | 2024 | 53 | 0.210 |
Why?
|
| Hepatitis A | 1 | 2024 | 28 | 0.210 |
Why?
|
| Organ Preservation | 1 | 2025 | 60 | 0.210 |
Why?
|
| Republic of Korea | 1 | 2024 | 44 | 0.210 |
Why?
|
| Telemedicine | 2 | 2023 | 513 | 0.200 |
Why?
|
| Perfusion | 1 | 2025 | 212 | 0.200 |
Why?
|
| Age Distribution | 3 | 2019 | 426 | 0.200 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2026 | 203 | 0.200 |
Why?
|
| Neoadjuvant Therapy | 1 | 2025 | 401 | 0.200 |
Why?
|
| Vascular Stiffness | 1 | 2024 | 82 | 0.200 |
Why?
|
| Policy | 1 | 2023 | 35 | 0.200 |
Why?
|
| Opiate Substitution Treatment | 2 | 2021 | 44 | 0.190 |
Why?
|
| Adolescent | 6 | 2024 | 20774 | 0.190 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2025 | 331 | 0.190 |
Why?
|
| Adenocarcinoma | 2 | 2023 | 987 | 0.190 |
Why?
|
| Glucocorticoids | 1 | 2025 | 341 | 0.190 |
Why?
|
| California | 2 | 2020 | 127 | 0.190 |
Why?
|
| Chi-Square Distribution | 3 | 2018 | 567 | 0.180 |
Why?
|
| Integrases | 1 | 2023 | 156 | 0.180 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2021 | 26 | 0.180 |
Why?
|
| Hepatitis B | 1 | 2023 | 172 | 0.170 |
Why?
|
| Prebiotics | 1 | 2021 | 28 | 0.170 |
Why?
|
| Viremia | 1 | 2022 | 131 | 0.170 |
Why?
|
| Alcohol Abstinence | 1 | 2021 | 15 | 0.170 |
Why?
|
| Cholestasis | 1 | 2023 | 164 | 0.170 |
Why?
|
| Health Care Rationing | 1 | 2021 | 59 | 0.170 |
Why?
|
| Gallbladder Neoplasms | 1 | 2021 | 15 | 0.170 |
Why?
|
| Military Personnel | 1 | 2023 | 214 | 0.170 |
Why?
|
| Hypernatremia | 1 | 2021 | 32 | 0.170 |
Why?
|
| Tacrolimus | 1 | 2021 | 104 | 0.170 |
Why?
|
| Age Factors | 4 | 2024 | 2844 | 0.170 |
Why?
|
| Hyponatremia | 1 | 2021 | 72 | 0.160 |
Why?
|
| Acute Kidney Injury | 2 | 2025 | 684 | 0.160 |
Why?
|
| Healthy Lifestyle | 1 | 2020 | 33 | 0.160 |
Why?
|
| Hepatitis B virus | 2 | 2023 | 137 | 0.160 |
Why?
|
| Vaccines, Synthetic | 1 | 2021 | 319 | 0.160 |
Why?
|
| Peritonitis | 2 | 2017 | 75 | 0.160 |
Why?
|
| Sarcopenia | 1 | 2021 | 56 | 0.160 |
Why?
|
| Dysbiosis | 1 | 2021 | 146 | 0.160 |
Why?
|
| Prediabetic State | 1 | 2021 | 66 | 0.160 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2020 | 75 | 0.160 |
Why?
|
| Exercise | 3 | 2021 | 866 | 0.160 |
Why?
|
| Multivariate Analysis | 3 | 2019 | 1387 | 0.160 |
Why?
|
| Biliary Atresia | 1 | 2023 | 220 | 0.160 |
Why?
|
| Digestive System Diseases | 1 | 2020 | 23 | 0.160 |
Why?
|
| Thyroid Gland | 1 | 2020 | 98 | 0.160 |
Why?
|
| Follow-Up Studies | 4 | 2025 | 5221 | 0.150 |
Why?
|
| Causality | 1 | 2019 | 91 | 0.150 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2023 | 1268 | 0.150 |
Why?
|
| Methadone | 1 | 2020 | 126 | 0.150 |
Why?
|
| Entamoebiasis | 1 | 2019 | 2 | 0.150 |
Why?
|
| Fibrosis | 4 | 2024 | 417 | 0.150 |
Why?
|
| Entamoeba histolytica | 1 | 2019 | 10 | 0.150 |
Why?
|
| Marijuana Smoking | 1 | 2019 | 31 | 0.140 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2020 | 231 | 0.140 |
Why?
|
| Phenols | 1 | 2019 | 71 | 0.140 |
Why?
|
| Colonic Diseases | 1 | 2019 | 36 | 0.140 |
Why?
|
| Analgesics, Opioid | 2 | 2021 | 470 | 0.140 |
Why?
|
| Drug Monitoring | 1 | 2021 | 285 | 0.140 |
Why?
|
| Marijuana Abuse | 1 | 2019 | 47 | 0.140 |
Why?
|
| Benzhydryl Compounds | 1 | 2019 | 76 | 0.140 |
Why?
|
| Sex Distribution | 1 | 2019 | 317 | 0.140 |
Why?
|
| Metabolic Syndrome | 1 | 2021 | 366 | 0.130 |
Why?
|
| Global Burden of Disease | 1 | 2017 | 35 | 0.130 |
Why?
|
| Rifamycins | 1 | 2017 | 18 | 0.130 |
Why?
|
| Bacterial Infections | 2 | 2017 | 322 | 0.130 |
Why?
|
| Licensed Practical Nurses | 1 | 2017 | 1 | 0.130 |
Why?
|
| Immunosuppressive Agents | 1 | 2021 | 658 | 0.130 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2021 | 326 | 0.130 |
Why?
|
| Sofosbuvir | 1 | 2017 | 20 | 0.130 |
Why?
|
| Hepatorenal Syndrome | 1 | 2017 | 31 | 0.130 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2017 | 32 | 0.130 |
Why?
|
| Thrombophilia | 1 | 2017 | 41 | 0.130 |
Why?
|
| Carbamates | 1 | 2017 | 66 | 0.130 |
Why?
|
| Nutritional Support | 1 | 2017 | 67 | 0.130 |
Why?
|
| United States Health Resources and Services Administration | 1 | 2016 | 3 | 0.130 |
Why?
|
| Time-to-Treatment | 1 | 2018 | 208 | 0.120 |
Why?
|
| Clostridium Infections | 1 | 2020 | 248 | 0.120 |
Why?
|
| Pancreatic Neoplasms | 1 | 2023 | 744 | 0.120 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2018 | 273 | 0.120 |
Why?
|
| Medically Underserved Area | 1 | 2017 | 88 | 0.120 |
Why?
|
| Heparin | 1 | 2017 | 204 | 0.120 |
Why?
|
| Case-Control Studies | 2 | 2023 | 3413 | 0.120 |
Why?
|
| Income | 1 | 2016 | 135 | 0.120 |
Why?
|
| RNA, Messenger | 1 | 2021 | 2556 | 0.120 |
Why?
|
| Computed Tomography Angiography | 1 | 2017 | 215 | 0.120 |
Why?
|
| Nutritional Status | 1 | 2017 | 301 | 0.120 |
Why?
|
| Malnutrition | 1 | 2017 | 156 | 0.110 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 1165 | 0.110 |
Why?
|
| Survival Analysis | 4 | 2022 | 1509 | 0.110 |
Why?
|
| Educational Status | 1 | 2016 | 275 | 0.110 |
Why?
|
| Insurance, Health | 1 | 2016 | 139 | 0.110 |
Why?
|
| Lymph Node Excision | 1 | 2016 | 164 | 0.110 |
Why?
|
| Decision Support Techniques | 1 | 2018 | 296 | 0.110 |
Why?
|
| Health Resources | 1 | 2016 | 127 | 0.110 |
Why?
|
| Heterozygote | 1 | 2017 | 722 | 0.110 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2020 | 772 | 0.110 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2016 | 253 | 0.110 |
Why?
|
| Survival Rate | 4 | 2020 | 2136 | 0.100 |
Why?
|
| Lymph Nodes | 1 | 2016 | 361 | 0.100 |
Why?
|
| Health Services Accessibility | 2 | 2017 | 696 | 0.100 |
Why?
|
| Logistic Models | 3 | 2025 | 1814 | 0.100 |
Why?
|
| Allografts | 2 | 2025 | 218 | 0.090 |
Why?
|
| Anticoagulants | 1 | 2017 | 597 | 0.090 |
Why?
|
| Kidney | 1 | 2019 | 1283 | 0.090 |
Why?
|
| Veterans | 1 | 2023 | 1792 | 0.090 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2016 | 489 | 0.090 |
Why?
|
| Decision Making | 1 | 2016 | 689 | 0.090 |
Why?
|
| Prospective Studies | 4 | 2023 | 6475 | 0.080 |
Why?
|
| Comorbidity | 3 | 2023 | 1595 | 0.080 |
Why?
|
| Kidney Failure, Chronic | 1 | 2019 | 941 | 0.080 |
Why?
|
| Morbidity | 2 | 2023 | 260 | 0.080 |
Why?
|
| Hepatitis B Surface Antigens | 2 | 2023 | 59 | 0.080 |
Why?
|
| Prognosis | 4 | 2023 | 4927 | 0.080 |
Why?
|
| Medicaid | 2 | 2023 | 251 | 0.080 |
Why?
|
| Observational Studies as Topic | 2 | 2023 | 98 | 0.080 |
Why?
|
| ROC Curve | 2 | 2023 | 616 | 0.080 |
Why?
|
| Stomach Neoplasms | 1 | 2016 | 579 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2025 | 1246 | 0.080 |
Why?
|
| Chronic Disease | 3 | 2018 | 1232 | 0.080 |
Why?
|
| Censuses | 2 | 2019 | 9 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 2097 | 0.070 |
Why?
|
| Child | 3 | 2024 | 26145 | 0.070 |
Why?
|
| Sex Factors | 2 | 2024 | 1336 | 0.070 |
Why?
|
| Biopsy | 2 | 2023 | 1238 | 0.070 |
Why?
|
| Linear Models | 2 | 2020 | 690 | 0.070 |
Why?
|
| SEER Program | 2 | 2021 | 213 | 0.070 |
Why?
|
| Quality of Life | 1 | 2017 | 2087 | 0.070 |
Why?
|
| Ultrasonography | 2 | 2024 | 972 | 0.070 |
Why?
|
| Body Mass Index | 2 | 2024 | 1684 | 0.060 |
Why?
|
| Odds Ratio | 2 | 2021 | 1228 | 0.060 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 2551 | 0.060 |
Why?
|
| Renal Dialysis | 2 | 2025 | 950 | 0.060 |
Why?
|
| Prednisolone | 1 | 2025 | 71 | 0.050 |
Why?
|
| North America | 1 | 2025 | 259 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 2 | 2018 | 543 | 0.050 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2024 | 33 | 0.050 |
Why?
|
| Primary Graft Dysfunction | 1 | 2025 | 41 | 0.050 |
Why?
|
| Agent Orange | 1 | 2023 | 3 | 0.050 |
Why?
|
| Neoplasms | 1 | 2019 | 2951 | 0.050 |
Why?
|
| Drug Therapy, Combination | 2 | 2018 | 1165 | 0.050 |
Why?
|
| Reperfusion Injury | 1 | 2025 | 108 | 0.050 |
Why?
|
| Electronic Health Records | 2 | 2023 | 812 | 0.050 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2023 | 85 | 0.050 |
Why?
|
| Mutation | 1 | 2017 | 6139 | 0.050 |
Why?
|
| Food Supply | 1 | 2024 | 91 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2020 | 2306 | 0.050 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2023 | 103 | 0.050 |
Why?
|
| Hand Strength | 1 | 2022 | 56 | 0.050 |
Why?
|
| Living Donors | 1 | 2023 | 112 | 0.050 |
Why?
|
| Ethanol | 1 | 2023 | 164 | 0.050 |
Why?
|
| Muscle Strength | 1 | 2022 | 82 | 0.050 |
Why?
|
| Acute Disease | 1 | 2025 | 1150 | 0.040 |
Why?
|
| Ontario | 1 | 2021 | 88 | 0.040 |
Why?
|
| Estradiol | 1 | 2023 | 476 | 0.040 |
Why?
|
| Early Diagnosis | 1 | 2022 | 191 | 0.040 |
Why?
|
| alpha-Fetoproteins | 1 | 2022 | 138 | 0.040 |
Why?
|
| Graft Rejection | 1 | 2025 | 558 | 0.040 |
Why?
|
| Insurance Coverage | 1 | 2021 | 116 | 0.040 |
Why?
|
| Hypoglycemic Agents | 1 | 2024 | 475 | 0.040 |
Why?
|
| Respiratory Protective Devices | 1 | 2020 | 8 | 0.040 |
Why?
|
| Sodium | 1 | 2021 | 279 | 0.040 |
Why?
|
| Animals | 1 | 2021 | 33899 | 0.040 |
Why?
|
| Obesity | 2 | 2024 | 2389 | 0.040 |
Why?
|
| Aspartate Aminotransferases | 1 | 2020 | 80 | 0.040 |
Why?
|
| Platelet Count | 1 | 2020 | 139 | 0.040 |
Why?
|
| Death Certificates | 1 | 2019 | 10 | 0.040 |
Why?
|
| Alanine Transaminase | 1 | 2020 | 156 | 0.040 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2023 | 718 | 0.040 |
Why?
|
| Paromomycin | 1 | 2019 | 5 | 0.040 |
Why?
|
| Protective Factors | 1 | 2019 | 93 | 0.040 |
Why?
|
| Weight Loss | 1 | 2023 | 526 | 0.040 |
Why?
|
| Thyrotropin | 1 | 2018 | 50 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2019 | 101 | 0.040 |
Why?
|
| Antiprotozoal Agents | 1 | 2019 | 42 | 0.040 |
Why?
|
| Risk | 1 | 2020 | 734 | 0.040 |
Why?
|
| Early Detection of Cancer | 1 | 2022 | 418 | 0.030 |
Why?
|
| Testosterone | 1 | 2023 | 590 | 0.030 |
Why?
|
| Sustained Virologic Response | 1 | 2018 | 47 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2020 | 468 | 0.030 |
Why?
|
| Myositis | 1 | 2019 | 106 | 0.030 |
Why?
|
| Hepatitis B e Antigens | 1 | 2016 | 14 | 0.030 |
Why?
|
| Patient Portals | 1 | 2017 | 19 | 0.030 |
Why?
|
| Ambulatory Care | 1 | 2020 | 405 | 0.030 |
Why?
|
| Markov Chains | 1 | 2017 | 100 | 0.030 |
Why?
|
| Computer Security | 1 | 2017 | 31 | 0.030 |
Why?
|
| Nutrition Assessment | 1 | 2017 | 126 | 0.030 |
Why?
|
| Advanced Practice Nursing | 1 | 2016 | 8 | 0.030 |
Why?
|
| Polyethylene Glycols | 1 | 2018 | 235 | 0.030 |
Why?
|
| Colonoscopy | 1 | 2019 | 246 | 0.030 |
Why?
|
| Immunization, Passive | 1 | 2016 | 122 | 0.030 |
Why?
|
| Confidentiality | 1 | 2017 | 105 | 0.030 |
Why?
|
| Interferon-alpha | 1 | 2018 | 240 | 0.030 |
Why?
|
| Safety-net Providers | 1 | 2017 | 87 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2017 | 278 | 0.030 |
Why?
|
| Postoperative Care | 1 | 2018 | 297 | 0.030 |
Why?
|
| Glomerular Filtration Rate | 1 | 2019 | 567 | 0.030 |
Why?
|
| Preoperative Care | 1 | 2018 | 356 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2019 | 559 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 314 | 0.030 |
Why?
|
| Biomarkers | 1 | 2025 | 3397 | 0.030 |
Why?
|
| Palliative Care | 1 | 2019 | 444 | 0.030 |
Why?
|
| Health Personnel | 1 | 2020 | 547 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 1486 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2017 | 698 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2016 | 426 | 0.030 |
Why?
|
| Muscle, Skeletal | 1 | 2021 | 1001 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2018 | 1312 | 0.030 |
Why?
|
| Patient Selection | 1 | 2018 | 721 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2024 | 1423 | 0.030 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 496 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2022 | 1603 | 0.030 |
Why?
|
| Anxiety | 1 | 2020 | 1003 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 1298 | 0.020 |
Why?
|
| Algorithms | 1 | 2020 | 1680 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 1892 | 0.020 |
Why?
|
| Cesarean Section | 1 | 2016 | 435 | 0.020 |
Why?
|
| Diet | 1 | 2020 | 1115 | 0.020 |
Why?
|
| Communication | 1 | 2017 | 528 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2020 | 8553 | 0.020 |
Why?
|
| Infant | 1 | 2020 | 13306 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2020 | 14987 | 0.010 |
Why?
|
| Pregnancy | 1 | 2016 | 7492 | 0.010 |
Why?
|